The studies were conducted by the Company's partners including
The two Phase 3 multi-centre, randomized, vehicle-controlled, double-blind, parallel group trials were conducted in
This is the first of two dermatological products being developed in collaboration with our partners. Under the terms of the collaboration, Crescita utilized its proprietary MMPE technology to formulate two patented topical dermatology product candidates.
About
Crescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products for the treatment and care of skin conditions, diseases and their symptoms and prescription drug products for the treatment of pain. Crescita owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active drugs into or through the skin.
Supported by a sales force covering
Crescita developed a prescription product called Pliaglis that utilizes our proprietary phase-changing topical cream Peel technology. Pliaglis is a topical local anaesthetic cream that provides safe and effective local dermal analgesia on intact skin prior to superficial dermatological procedures. The product is currently approved in over 25 different countries and sold by commercial partners in the
Crescita also provides contract development and manufacturing services to several local and North American clients. Our contract development and manufacturing organization infrastructure allows Crescita to provide its clients with development and other support activities required to bring their products to market. Crescita has extensive expertise in product formulation and development, leveraging our patented transdermal delivery technologies, and specializes in manufacturing creams, liquids, gels ointments and serums. The Company operates out of a 50,000 square-foot manufacturing facility located in
About MMPE
The MMPE technology uses synergistic combinations of certain pharmaceutical excipients included on the
About
Forward-Looking Information Cautionary Statement
This press release contains 'forward-looking information' as defined under Canadian securities laws (collectively, 'forward-looking statements'). The words 'plans', 'expects', 'does not expect', 'goals', 'seek', 'strategy', 'future', 'estimates', 'intends', 'anticipates', 'does not anticipate', 'projected', 'believes' or variations of such words and phrases or statements to the effect that certain actions, events or results 'may', 'will', 'could', 'would', 'should', 'might', 'likely', 'occur', 'be achieved' or 'continue' and similar expressions identify forward-looking statements. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking statements.
Forward-looking statements are not historical facts but instead represent management's expectations, estimates, projections and assumptions regarding future events or circumstances. Such forward-looking statements are qualified in their entirety by the inherent risks, uncertainties and changes in circumstances surrounding future expectations which are difficult to predict and many of which are beyond the control of the Company. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable by management of the Company as of the date of this press release, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Material factors and assumptions used to develop the forward-looking statements, and material risk factors that could cause actual results to differ materially from the forward-looking statements, include but are not limited to changes in the business or affairs of Crescita; the ability of Crescita's licensees to successfully market its products; competitive factors in the industries in which Crescita operates; relationships with customers, suppliers and licensees; changes in legal and regulatory requirements; foreign exchange and interest rates; prevailing economic conditions and other factors, many of which are beyond the control of Crescita.
Additional factors that could cause Crescita's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the risk factors included in Crescita's most recent Annual Information Form dated
Contact:
Tel: 1.905.326.1888
Email: glen@bristolir.com
(C) 2020 Electronic News Publishing, source